Clinical Practice Points • p.E749Q is an uncommon EGFR mutation in exon 19 with unknown clinical significance. • A patient with lung adenocarcinoma harboring the p.E749Q EGFR mutation does not respond to gefitinib. • The p.E749Q mutation seems to be correlated with resistance to tyrosine kinase inhibitors. • Conventional chemotherapy should be the treatment of choice in patients with the p.E749Q mutation.
Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma / Genestreti, Giovenzio; de Biase, Dario; Di Battista, Monica; Cavallo, Giovanna; Degli Esposti, Roberta; Visani, Michela; Acquaviva, Giorgia; Brand, Thomas; Pession, Annalisa; Tallini, Giovanni; Brandes, Alba A.. - In: CLINICAL LUNG CANCER. - ISSN 1525-7304. - ELETTRONICO. - 18:3(2017), pp. e215-e217. [10.1016/j.cllc.2017.01.003]
Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma
DE BIASE, DARIO;DI BATTISTA, MONICA;VISANI, MICHELA;ACQUAVIVA, GIORGIA;PESSION, ANNALISA;TALLINI, GIOVANNI;
2017
Abstract
Clinical Practice Points • p.E749Q is an uncommon EGFR mutation in exon 19 with unknown clinical significance. • A patient with lung adenocarcinoma harboring the p.E749Q EGFR mutation does not respond to gefitinib. • The p.E749Q mutation seems to be correlated with resistance to tyrosine kinase inhibitors. • Conventional chemotherapy should be the treatment of choice in patients with the p.E749Q mutation.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
